Treatment of heart rhythym disorders by administration of 3-phenylsulfonyl-3, 7-diazabicyclo[3.3.1]nonane compounds

The use of 3,7,9,9-tetrasubstituted 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds for treating cardiac arrhythmias in larger mammals, including humans; novel antiarrhythmically active 3,7,9,9-tetrasubstituted compounds corresponding to the general formula Ia Ia in which R1 is an alkyl group having 1-6 carbon atoms or a cycloalkylalkyl group having 4-7 carbon atoms, R2 is lower alkyl, and R3 is lower alkyl, or R2 and R3 together form an alkylene chain having 3-6 carbon atoms, R4' is cyano, an R6-O-CO- group in which R6 is lower alkyl, an R7-SO2-NH- group in which R7 is lower alkyl, or an R8-CO-NH- group in which R8 is lower alkyl or a phenyl group which is optionally substituted by halogen, cyano, nitro or an R9-SO2- radical in which R9 is lower alkyl, or an imidazolyl radical located in position 4 of the phenyl ring, and R5 is hydrogen or halogen, and physiologically acceptable acid addition salts thereof, and processes and intermediates for preparing them.